Press Releases Latest Sep 26, 2023 Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates Press Releases Year None20232022202120202019201820172016201520142013 Sep 16, 2021 Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021 Sep 07, 2021 Theratechnologies to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Sep 01, 2021 Theratechnologies to Host Key Opinion Leader Event to Discuss Tesamorelin for the Treatment of Non-Alcoholic Steatohepatitis (NASH) Aug 13, 2021 Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science Aug 04, 2021 Theratechnologies to Present at the Canaccord Genuity 41st Annual Growth Conference Jul 23, 2021 Theratechnologies Establishes New At-The-Market Facility Jul 15, 2021 Theratechnologies Reports Financial Results for the Second Quarter of Fiscal 2021 and Provides Update on Its Planned Phase 3 Clinical Trial in NASH Jun 30, 2021 Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021 Jun 23, 2021 Theratechnologies Appoints New Board Member Jun 21, 2021 Theratechnologies Announces New Preclinical Findings for Its Lead Investigational Peptide-Drug Conjugate TH1902 for the Potential Treatment of Metastatic Cancers First page « Previous page ‹ … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page › Last page » Displaying 71 - 80 of 328
Sep 26, 2023 Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
Sep 16, 2021 Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021
Sep 07, 2021 Theratechnologies to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 01, 2021 Theratechnologies to Host Key Opinion Leader Event to Discuss Tesamorelin for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Aug 13, 2021 Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science
Jul 15, 2021 Theratechnologies Reports Financial Results for the Second Quarter of Fiscal 2021 and Provides Update on Its Planned Phase 3 Clinical Trial in NASH
Jun 21, 2021 Theratechnologies Announces New Preclinical Findings for Its Lead Investigational Peptide-Drug Conjugate TH1902 for the Potential Treatment of Metastatic Cancers
